<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01569763</url>
  </required_header>
  <id_info>
    <org_study_id>CIP0005</org_study_id>
    <nct_id>NCT01569763</nct_id>
  </id_info>
  <brief_title>Minerva Pivotal Study to Evaluate Safety and Efficacy of the Aurora Endometrial Ablation System Compared to Hysteroscopic Rollerball Ablation</brief_title>
  <official_title>Minerva Pivotal Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Minerva Surgical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Minerva Surgical, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the safety and effectiveness of the Aurora
      Endometrial Ablation System as compared to hysteroscopic rollerball endometrial ablation in
      reducing menstrual blood loss at 12 months post-treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Menorrhagia is defined as menstrual bleeding in the ovulatory woman exceeding 80 ml per
      month. Approximately 20-25% of healthy premenopausal women have abnormal uterine bleeding.
      Menorrhagia can have a negative impact on a woman's lifestyle and self-perception, often
      leading her to seek definitive treatment. Pharmacologic treatment for menorrhagia is not
      always successful, and dilatation and curettage typically provides relief for only a few
      menstrual cycles. Traditionally hysterectomy has been the definitive treatment for
      menorrhagia. This clinical study evaluates the safety and effectiveness of the Aurora
      Endometrial Ablation System to provide a therapeutic treatment for menorrhagia due to benign
      causes by ablating the endometrial lining of the uterus in pre-menopausal women for whom
      childbearing is complete. Subjects who are randomized to the control group will receive
      hysteroscopic rollerball/resection ablation. Subjects randomized to the test arm will be
      treated with the Aurora Endometrial Ablation System.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">March 2, 2018</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of Menstrual Bleeding to Normal or Below Normal at 12 Months</measure>
    <time_frame>12 months</time_frame>
    <description>Clinical success was defined as a reduction in menstrual bleeding volume to ≤ 80 ml as measured by the alkaline hematin method (AH). Clinical success was not achieved if: (1) at one year post-treatment menstrual blood loss is greater than 80ml, as measured by AH; (2) an acute failure occurred (e.g., aborted procedure, etc.); or (3) the subject required additional therapy to control menorrhagia.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Procedure Time</measure>
    <time_frame>&lt; 1 hour</time_frame>
    <description>Procedure time is defined as the time from device insertion to time of device removal.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">153</enrollment>
  <condition>Menorrhagia</condition>
  <arm_group>
    <arm_group_label>hysteroscopic rollerball resection/ablation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Aurora Endometrial Ablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Aurora Endometrial Ablation</intervention_name>
    <description>Endometrial Ablation using the Aurora Endometrial Ablation system</description>
    <arm_group_label>Aurora Endometrial Ablation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Rollerball Ablation/Resection</intervention_name>
    <description>Hysteroscopic rollerball resection/ablation</description>
    <arm_group_label>hysteroscopic rollerball resection/ablation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Refractory menorrhagia with no definable organic cause

          -  Female subject from (and including) age 25 to 50 years

          -  Uterine sound measurement of no greater than10.0cm (external os to internal fundus)
             and a minimum uterine cavity length of 4.0cm

          -  A minimum menstrual blood loss of ≥ 160 ml for two baseline cycles within three months
             prior to treatment as measured by alkaline hematin extraction; OR,

               -  A minimum menstrual blood loss of ≥ 160 ml for one baseline cycle for women who
                  either

               -  had at least 3 prior months documented failed medical therapy; or

               -  had a contraindication to medical therapy

          -  Premenopausal at enrollment as determined by FSH measurement ≤ 40 IU/L

          -  Not pregnant and no desire to conceive at any time

          -  Subject agrees to use a reliable form of contraception up to the 12-month follow-up
             visit. If a hormonal birth control method is used for contraception, the subject must
             have been on said method for ≥ 3 months prior to enrollment and agrees to remain on
             the same hormonal regimen through the initial 12-month follow-up

          -  Able to provide written informed consent using a form that has been approved by the
             reviewing IRB/EC

          -  Subject agrees to follow-up exams and data collection requirements

          -  Subject who is literate or demonstrates an understanding on how to collect menstrual
             blood loss products for the alkaline hematin method of analysis

        Exclusion Criteria:

          -  Pregnancy or subject with a desire to conceive

          -  Endometrial hyperplasia as confirmed by histology

          -  Presence of active endometritis

          -  Active pelvic inflammatory disease

          -  Active sexually transmitted disease (STD)

          -  Presence of bacteremia, sepsis, or other active systemic infection

          -  Active infection of the genitals, vagina, cervix, uterus or urinary tract at the time
             of the procedure

          -  Known/suspected abdominal pelvic or gynecological malignancy within the past 5 years

          -  Known clotting defects or bleeding disorders

          -  Untreated/unevaluated cervical dysplasia, except CIN I

          -  Prior uterine surgery (except low segment cesarean section) that interrupts the
             integrity of the uterine wall (e.g., transmural myomectomy or classical cesarean
             section)

          -  Previous endometrial ablation procedure

          -  Presence of an implantable (intrauterine) contraceptive device (e.g. Essure™ or
             Adiana™)

          -  Currently on medications that could thin the myometrial muscle, such as long-term
             steroid use (except inhaler or nasal therapy for asthma)

          -  Currently on anticoagulants

          -  Abnormal or obstructed cavity as confirmed by hysteroscopy, SIS or vaginal ultrasound

          -  Presence of an intrauterine device (IUD) which the Subject is unwilling to have
             removed at the time of the operative visit

          -  Subject currently on hormonal birth control therapy (including the Mirena device) for
             &lt;3 months prior to enrollment

          -  Subject who is unwilling to use birth control post-ablation whether non-hormonal birth
             control or the same hormonal birth control therapy as before the procedure

          -  Subject who is within 6-weeks post partum

          -  Any subject who is currently participating or considers future participation in a
             research study of an investigational drug or device during the course of this
             investigational study

          -  Any general health condition which, in the opinion of the Investigator, could
             represent an increased risk for the subject
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eugene Skalnyi, MD</last_name>
    <role>Study Director</role>
    <affiliation>Minerva Surgical, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New Horizons Women's Care</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's Health Research</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Basinski, LLC</name>
      <address>
        <city>Newburgh</city>
        <state>Indiana</state>
        <zip>47630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cypress Medical Research Center, LLC</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Gynecology and Surgery</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Clinic Minimally Invasive Gynecology</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Women's Care PC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Research Institute</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McMaster University/Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital LaSalle</name>
      <address>
        <city>Ville Lassalle</city>
        <state>Quebec</state>
        <zip>H8P 1C1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regina Qu'Appelle Health Region</name>
      <address>
        <city>Regina</city>
        <state>Saskatchewan</state>
        <zip>S4S 6X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>La Cite Medicale</name>
      <address>
        <city>Quebec</city>
        <zip>G1W 2J5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario, UANL</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Mexico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2012</study_first_submitted>
  <study_first_submitted_qc>March 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2012</study_first_posted>
  <results_first_submitted>April 1, 2016</results_first_submitted>
  <results_first_submitted_qc>April 1, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 5, 2016</results_first_posted>
  <last_update_submitted>March 20, 2018</last_update_submitted>
  <last_update_submitted_qc>March 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>endometrial ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Menorrhagia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were enrolled in the clinical trial at 13 Investigational Sites in the U.S., Canada, and Mexico between March 2012 until November 2013.</recruitment_details>
      <pre_assignment_details>A total of 153 subjects were enrolled and randomized 2:1 to the Minerva (Aurora) Test Group (n=102) or the Rollerball Control Group (n=51). As part of the randomization process, subjects were stratified by age, though there was no attempt to enroll an equal number into the &lt; 40 and &gt; 40 age groups. All 153 subjects were successfully treated.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Aurora Endometrial Ablation</title>
          <description>Aurora Endometrial Ablation: Endometrial Ablation using the Aurora Endometrial Ablation system</description>
        </group>
        <group group_id="P2">
          <title>Hysteroscopic Rollerball Resection/Ablation</title>
          <description>Rollerball Ablation/Resection: Hysteroscopic rollerball resection/ablation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="102"/>
                <participants group_id="P2" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="102"/>
                <participants group_id="P2" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="99">Completed 12 Months of Follow-up</participants>
                <participants group_id="P2" count="44">Completed 12 Months of Follow-up</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Enrolled Subjects</population>
      <group_list>
        <group group_id="B1">
          <title>Aurora Endometrial Ablation</title>
          <description>Aurora Endometrial Ablation: Endometrial Ablation using the Minerva Endometrial Ablation system</description>
        </group>
        <group group_id="B2">
          <title>Hysteroscopic Rollerball Resection/Ablation</title>
          <description>Rollerball Ablation/Resection: Hysteroscopic rollerball resection/ablation</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="102"/>
            <count group_id="B2" value="51"/>
            <count group_id="B3" value="153"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.6" spread="4.2"/>
                    <measurement group_id="B2" value="42.5" spread="4.7"/>
                    <measurement group_id="B3" value="42.5" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="153"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alkaline Hematin Value at Baseline</title>
          <description>Alkaline hematin methodology is a quantitative laboratory method used to evaluate the volume of menstrual blood loss, by collecting used sanitary products (tampons and pads) and extracting alkaline hematin from the hemoglobin from menstrual fluids.</description>
          <units>Menstrual Blood Loss (ml)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="310.2" spread="169.0"/>
                    <measurement group_id="B2" value="301.8" spread="176.1"/>
                    <measurement group_id="B3" value="307.4" spread="170.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Reduction of Menstrual Bleeding to Normal or Below Normal at 12 Months</title>
        <description>Clinical success was defined as a reduction in menstrual bleeding volume to ≤ 80 ml as measured by the alkaline hematin method (AH). Clinical success was not achieved if: (1) at one year post-treatment menstrual blood loss is greater than 80ml, as measured by AH; (2) an acute failure occurred (e.g., aborted procedure, etc.); or (3) the subject required additional therapy to control menorrhagia.</description>
        <time_frame>12 months</time_frame>
        <population>All Randomized subjects in whom treatment was attempted</population>
        <group_list>
          <group group_id="O1">
            <title>Aurora Endometrial Ablation</title>
            <description>Aurora Endometrial Ablation: Endometrial Ablation using the Aurora Endometrial Ablation system</description>
          </group>
          <group group_id="O2">
            <title>Hysteroscopic Rollerball Resection/Ablation</title>
            <description>Rollerball Ablation/Resection: Hysteroscopic rollerball resection/ablation</description>
          </group>
        </group_list>
        <measure>
          <title>Reduction of Menstrual Bleeding to Normal or Below Normal at 12 Months</title>
          <description>Clinical success was defined as a reduction in menstrual bleeding volume to ≤ 80 ml as measured by the alkaline hematin method (AH). Clinical success was not achieved if: (1) at one year post-treatment menstrual blood loss is greater than 80ml, as measured by AH; (2) an acute failure occurred (e.g., aborted procedure, etc.); or (3) the subject required additional therapy to control menorrhagia.</description>
          <population>All Randomized subjects in whom treatment was attempted</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Procedure Time</title>
        <description>Procedure time is defined as the time from device insertion to time of device removal.</description>
        <time_frame>&lt; 1 hour</time_frame>
        <population>Subjects completing treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Aurora Endometrial Ablation</title>
            <description>Aurora Endometrial Ablation: Endometrial Ablation using the Aurora Endometrial Ablation system</description>
          </group>
          <group group_id="O2">
            <title>Hysteroscopic Rollerball Resection/Ablation</title>
            <description>Rollerball Ablation/Resection: Hysteroscopic rollerball resection/ablation</description>
          </group>
        </group_list>
        <measure>
          <title>Procedure Time</title>
          <description>Procedure time is defined as the time from device insertion to time of device removal.</description>
          <population>Subjects completing treatment</population>
          <units>Minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="0.5"/>
                    <measurement group_id="O2" value="17.2" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Subjects With Amenorrhea at 12 Months</title>
        <description>Amenorrhea at 12 Months- Number of Subjects experiencing no menstrual bleeding</description>
        <time_frame>12 Months</time_frame>
        <population>Randomized subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Aurora Endometrial Ablation</title>
            <description>Aurora Endometrial Ablation: Endometrial Ablation using the Aurora Endometrial Ablation system</description>
          </group>
          <group group_id="O2">
            <title>Hysteroscopic Rollerball Resection/Ablation</title>
            <description>Rollerball Ablation/Resection: Hysteroscopic rollerball resection/ablation</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With Amenorrhea at 12 Months</title>
          <description>Amenorrhea at 12 Months- Number of Subjects experiencing no menstrual bleeding</description>
          <population>Randomized subjects</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <desc>All Serious Adverse Events observed during the clinical study, regardless of relationship to the study device or procedure are reported below. All non-Serious Adverse Events considered possibly, probably or highly probably related to the device or procedure are reported below.</desc>
      <group_list>
        <group group_id="E1">
          <title>Aurora Endometrial Ablation</title>
          <description>Aurora Endometrial Ablation: Endometrial Ablation using the Aurora Endometrial Ablation system</description>
        </group>
        <group group_id="E2">
          <title>Hysteroscopic Rollerball Resection/Ablation</title>
          <description>Rollerball Ablation/Resection: Hysteroscopic rollerball resection/ablation</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Thyroid Nodule</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Myeloma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Endometritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Pelvic Inflammatory Disease (PID)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Continued Heavy Menstrual Bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Anesthesia Related</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea and/or Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Abdominal Pain and/or Bloating</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="102"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Weaknes, Fatigue, Sleepiness, Lack of concentration, Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Backache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Bleeding or spotting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Pelvic Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Vaginal discharge, unpleasant smell, burning, abnormal sensation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Endometritis or Endomyometritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Pelvic Inflammatory Disease (PID)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Hematometra</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Dysmenorrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin Rash and/or Itching or Burning Sensation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Investigator has the right to publish their research for non-profit and academic purposes, provided the 1st publication of results shall be in conjunction with results from all centers in this Study. If Investigator desires to publish/present data obtained by Investigator, following completion of the Study at all sites, Investigator may do so, provided a copy of proposed publication/presentation is received by Company for review/comment at least 15 days in advance of submission for publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Eugene Skalnyi, VP Medical Affairs</name_or_title>
      <organization>Minerva Surgical, Inc.</organization>
      <phone>(1) 650-284-3500</phone>
      <email>Eugenes@minervasurgical.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

